| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6193936 | Urologic Oncology: Seminars and Original Investigations | 2016 | 9 Pages |
Abstract
The results of this nonrandomized, observational study suggest that first-line taxane therapy may benefit senior adults with mCRPC more than alternative therapies. Treatment decisions should not be based on chronological age.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jean-Pierre M.D., Eleni M.D., Asif M.D., Paula M.D., Choung M.D., Ali M.D., Axel M.D., José Augusto M.D., Simon Hitier, Haluk M.D.,